Skip to content
PHARMACEUTICAL PREPARATIONS

Lipella Pharmaceuticals Inc. LIPO

4 fiscal years on record · USD · FY2024 reported · SEC filings only
$536,357
▲ 19.3% YoY
$-5.0M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

We have not yet commercialized any products, and we do not expect to generate revenue from sales of any product candidates for several years. Consistent with our strategy, we are currently addressing two indications via development of our product candidates, which we have designated as LP-10 for the indication of hemorrhagic cystitis (“HC”) and LP-310 for the indication of oral lichen planus (“OLP”) LP-310 employs a formulation similar to LP-10, for the treatment of OLP.

Written from the business description in Lipella Pharmaceuticals Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 28 March 2025. Every sentence was checked against that document before publication.

Growth

USD 536,357.00
Revenue, FY2024 · full 4-year series below
Revenue $M Net income $M
FY2024 · Revenue 0.5 · Net income -5.0
-2M-4M
20212024
Compound annual growth
+27.4%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−935 cents
lost on every revenue dollar
Operating margin Net margin
FY2024 · Operating -947.2% · Net -935.2%
-500%-1000%
202120222024
ROE
FY2024 · ROE -198.1%
-50%-100%-150%
202120222024
Three returns, three denominators.

Each USD of equity lost 198 cents this year.

Cash & shareholders

·
returned in FY2024 · dividends + net buybacks

Total assetsUSD 2.7M
EquityUSD 1.9M
CashUSD 2.2M
Gross debtUSD 0.00
Net debtUSD -2.2M
Current ratio3.47×

The company holds more cash than debt.

The 4-year record

4 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
LIPO, 4-year financial record
Metric 2024202320222021
Revenue $B0.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.0
Income tax $B◌◌◌◌
Net income $B−0.0−0.0−0.0−0.0
Free cash flow $B◌−0.0◌◌
EPS, diluted $−4.79−6.16−0.64−0.55
Dividend / sh $◌◌◌◌
Payout % — not applicable: no dividend————
ROE %−198.1−118.1−85.2−131.0
Shares out B0.000.000.000.00

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 16 reconciliationsAUDITED

Reconciled in 4 of the 4 fiscal years we could check. 28 checks were skipped: the balance sheet is not tagged before 2021. 14 checks were skipped: EPS is not tagged before 2021.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onnot stated in the filings
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categoryemerging growth company
Data on record since2021

Share this section

Download image